VTGN (Vistagen Therapeutics) Quality Rank


VTGN Vistagen Therapeutics Inc VTGN
29 GF Score
Price $0.24
GF Value $2.20
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Vistagen Therapeutics Quality Rank Related Terms

VTGN
29GF Score
Vistagen Therapeutics Inc VTGN
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vistagen Therapeutics (VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of $0.24 is trading 89.2% below its estimated GF Value™ of $2.20. GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.

Key valuation signals for VTGN:

  • Quality Rank:
  • GF Value™: $2.20 vs. price of $0.24 (89.2% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
29GF Score

Get the complete analysis for VTGN

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price
$2.20
GF Value